Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Improved Parkinson's Disease Motor Symptoms

Doses used in studies

mg/day: 1,000 (median 1,000, IQR 1,000–1,000) — 1 study
mg/kg/week: 50 (median 50, IQR 50–50) — 1 study

Time to effect

Median: 4.5 months · IQR 3.8 months–5.3 months · Range 3 months–6 months — Reported in 2 of 2 studies

2 of 2 papers

N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease.
- 2019-07-17
- RCT
- Clinical pharmacology and therapeutics 106(4)
- - Daniel A Monti
  - George Zabrecky
  - Daniel Kremens
  - Tsao-Wei Liang
  - Nancy A Wintering
  - Anthony J Bazzan
  - Li Zhong
  - Brendan K Bowens
  - Inna Chervoneva
  - Charles Intenzo
  - Andrew B Newberg
- PubMed: 31206613
- DOI: 10.1002/cpt.1548
4 Insights on
- Improved Parkinson's Disease Motor Symptoms
- High evidence
- Highly Cited
- Clinical
along with significantly improved PD symptoms (P < 0.0001)
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
50 mg/kg weekly intravenous infusions plus 500 mg oral twice per day for 3 months
N-Acetylcysteine is associated with changes in functional connectivity in patients with Parkinson's disease.
- 2026-03
- RCT
- Parkinsonism & related disorders 144
- - Daniel A Monti
  - George Zabrecky
  - Daniel Kremens
  - Tsao-Wei Liang
  - Nancy A Wintering
  - Faezeh Vedaei
  - Emily Navarreto
  - Monisha Gupta
  - Alicia Steinmetz
  - Anthony J Bazzan
  - Feroze Mohammed
  - Andrew B Newberg
- PubMed: 41619526
- DOI: 10.1016/j.parkreldis.2026.108216
2 Insights on
- Improved Parkinson's Disease Motor Symptoms
- High evidence
- Clinical
Changes in the precuneus also correlated with changes in UPDRS scores.
Effect
Beneficial
Effect size
Moderate
Significant
Yes
Dose
50 mg/kg weekly IV + 500 mg twice per day oral